deferasirox + deferoxamine

Deferasirox + deferoxamine is a combination of two iron chelators used to treat chronic iron overload, particularly in patients who have received multiple blood transfusions or have conditions such as non-transfusion-dependent thalassemia. Deferasirox is an oral small molecule that binds trivalent (ferric) iron, forming a stable complex that is primarily excreted via feces. It allows for once-daily oral dosing and selectively removes excess iron from the body[1][4][6]. Deferoxamine, also known as desferrioxamine or DFO, is a natural product derived from Streptomyces pilosus and acts as a chelating agent by binding free ferric iron (and aluminum), forming complexes that are eliminated through the kidneys. Unlike deferasirox, deferoxamine must be administered parenterally (usually intravenously or subcutaneously)[3][8]. Both agents reduce organ damage caused by excess iron but differ in their administration routes and pharmacokinetics. The combination of deferasirox and deferoxamine may be considered in cases where monotherapy with one chelator is insufficient for managing severe or refractory chronic iron overload. The safety and efficacy of combined use have not been fully established; clinical guidelines generally recommend monotherapy unless otherwise indicated.

Other names

DFOdesferrioxamine